Literature DB >> 9406893

Stimulated release of the beta-amyloid protein of Alzheimer's disease by normal human platelets.

C C Smith1.   

Abstract

The circulatory system is a potential source of the beta-amyloid protein (A beta) of ageing and Alzheimer's disease (AD), platelets accounting for the bulk of A beta immunoreactivity detectable in blood. Evidence for the release of A beta by platelets, however, has not been reported. Platelets from normal donors were therefore stimulated with collagen to establish if A beta immunoreactive material is released on activation. For comparison, the release of the platelet monoamines, serotonin (5-HT) adrenaline (Adr) and noradrenaline (NA) was also measured. Like the monoamines, collagen-induced A beta release was concentration-dependent, maximal stimulated release exceeding basal efflux by 184%. Collagen EC50 values for A beta release were similar to those for Adr and NA (3.6 +/- 0.6, 3.4 +/- 0.6 and 3.3 +/- 0.2 microg/ml collagen, respectively) but not 5-HT (9.8 +/- 1.9 microg/ml). These data provide the first evidence that platelets release A beta immunoreactive material on stimulation and may indicate that A beta, Adr and NA reside in the same subcellular compartment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406893     DOI: 10.1016/s0304-3940(97)00738-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.

Authors:  Daria Zamolodchikov; Sidney Strickland
Journal:  Blood       Date:  2012-01-11       Impact factor: 22.113

2.  Plasma Fibrinogen Is a Natural Deterrent to Amyloid Beta-Induced Platelet Activation.

Authors:  Vijay Sonkar; Paresh P Kulkarni; Susheel N Chaurasia; Ayusman Dash; Abhishek Jauhari; Devendra Parmar; Sanjay Yadav; Debabrata Dash
Journal:  Mol Med       Date:  2016-05-03       Impact factor: 6.354

3.  Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI).

Authors:  Paloma Bermejo-Bescós; Sagrario Martín-Aragón; Karim Jiménez-Aliaga; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel María Villar
Journal:  Neurochem Res       Date:  2013-04-11       Impact factor: 3.996

Review 4.  Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease.

Authors:  Edgar Dawkins; David H Small
Journal:  J Neurochem       Date:  2014-03-07       Impact factor: 5.372

Review 5.  Mitochondria and Mitochondrial Cascades in Alzheimer's Disease.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future?

Authors:  Simon M Bell; Katy Barnes; Matteo De Marco; Pamela J Shaw; Laura Ferraiuolo; Daniel J Blackburn; Annalena Venneri; Heather Mortiboys
Journal:  Biomedicines       Date:  2021-01-11

Review 7.  Peripheral Glycolysis in Neurodegenerative Diseases.

Authors:  Simon M Bell; Toby Burgess; James Lee; Daniel J Blackburn; Scott P Allen; Heather Mortiboys
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

8.  Alzheimer disease and platelets: how's that relevant.

Authors:  Silvia Catricala; Mauro Torti; Giovanni Ricevuti
Journal:  Immun Ageing       Date:  2012-09-17       Impact factor: 6.400

9.  Blood platelets in the progression of Alzheimer's disease.

Authors:  Nina S Gowert; Lili Donner; Madhumita Chatterjee; Yvonne S Eisele; Seyda T Towhid; Patrick Münzer; Britta Walker; Isabella Ogorek; Oliver Borst; Maria Grandoch; Martin Schaller; Jens W Fischer; Meinrad Gawaz; Sascha Weggen; Florian Lang; Mathias Jucker; Margitta Elvers
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

Review 10.  Contribution of blood platelets to vascular pathology in Alzheimer's disease.

Authors:  Wei Zhang; Wei Huang; Fang Jing
Journal:  J Blood Med       Date:  2013-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.